| Name | Title | Contact Details |
|---|
XNRGY Climate Systems is a Montreal-based company that designs, develops, and manufactures HVAC systems with a strong emphasis on energy efficiency and sustainability. Founded in 2017, the company aims to lead North America in sustainable design and advanced manufacturing of custom air handling systems, particularly for data centers, healthcare facilities, clean rooms, and life sciences environments. The company offers custom-engineered air handling units tailored to meet specific project requirements, focusing on reducing power usage effectiveness and carbon footprints. XNRGY specializes in thermal management solutions, ensuring optimal cooling and heating for mission-critical facilities. Its product lineup includes custom air handlers, energy recovery systems, and specialized materials designed to meet demanding specifications. XNRGY serves a diverse clientele, including major cloud and hyperscale data center operators, healthcare facilities, and life sciences organizations, ensuring high standards of air quality and efficiency.
GSB, formerly known as Guilford Savings Bank, is a mutual financial institution based in Connecticut, established in 1875. With over 145 years of experience, GSB has expanded from a single branch to eight locations, managing nearly $1 billion in assets. The bank focuses on community-oriented banking, emphasizing personalized service and long-term relationships with clients. GSB offers a comprehensive range of personal and business banking solutions. Their services include digital banking for real-time account management, tailored business banking for small to medium enterprises, and personal banking options such as checking and savings accounts, loans, and mortgages. The bank also provides specialized tools like online account opening and financial education resources. As a mutual bank, GSB reinvests its profits into community development and employee benefits, reflecting its commitment to local businesses and the shoreline communities of Connecticut. The bank promotes a culture of integrity and collaboration, ensuring that clients have direct access to staff and customized financial strategies. GSB continues to invest in digital innovation while maintaining a strong local presence.
Veteran Benefits Guide (VBG) is a benefit advisory company dedicated to assisting U.S. Armed Forces Veterans in maximizing their VA disability compensation ratings and benefits. Founded by Joshua Smith, a former Marine and VA rater, VBG provides pre-filing and post-filing consulting services. The company is headquartered in Las Vegas, Nevada, and has experienced significant growth since its inception in 2019. VBG employs a team of trained case managers, many of whom have backgrounds in the VA, to offer personalized guidance through the claims process. Their services include comprehensive reviews of military records, tailored claim strategies, and support for filing claims independently. VBG utilizes proprietary software to streamline the claims process and has a strong track record, boasting a 90% client success rate for favorable VA decisions and a perfect 5-star Google rating. The company emphasizes a Veteran-friendly approach, ensuring accuracy and efficiency in navigating the VAs Compensation & Pension process.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.